Observing the effect of nanocurcumin oral product in preventing cisplatin nephrotoxicity in cancer patients
Phase 2
- Conditions
- Cancer.
- Registration Number
- IRCT20200408046990N11
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients with cancer and candidates for chemotherapy with regimen containing cisplatin at a dose of 70mg/m2 every three weeks or 40mg/m2 weekly Patient age above 18 years and below 70 years GFR>60 ml/min At the start of chemotherapyNormal liver function Normality of patients' CBC
Exclusion Criteria
Allergy to curcuminPatient dissatisfactionReduction of patient's GFR below 45ml/min during treatmentReceiving other nephrotoxic drugs such as aminoglycosides, amphotericin, vancomycin Patients with chronic heart failure EF<60%Patients with untreated hypothyroidism or hyperthyroidismPatients with active infectionReceiving anti-inflammatory and antioxidant drugs at the same timeUnfavorable health status (PS<70%) based on karnofsky index
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum ceratinine level, BUN. Timepoint: ?At the beginning of each chemotherapy course. Method of measurement: Blood test.
- Secondary Outcome Measures
Name Time Method